Neoadjuvant treatment of soft-tissue sarcoma: A multimodality approach

Journal of Surgical Oncology

Volumn 101, Issue 4, 2010, Pages 327-333

  Reynoso, David ^a   Subbiah, Vivek ^a   Trent, Jonathan C ^a   Guadagnolo, B Ashleigh ^a   Lazar, Alexander J ^a   Benjamin, Robert ^a   Pollock, Raphael E ^a   Ludwig, Joseph A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant; Biomarkers; Cancer; Chemotherapy; Surgery; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; IMATINIB; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HUMAN; LIMB SALVAGE; MEDICAL LITERATURE; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; REVIEW; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ANTINEOPLASTIC AGENTS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; SARCOMA;

EID: 77749240348     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21481     Document Type: Review

References (44)

1. Kattan MW, Leung DH, Brennan MF: Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791-796.
2. Mariani L, Miceli R, Kattan MW, et al.: Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005;103:402-408.
3. Ravdin PM, Siminoff LA, Davis GJ, et al.: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.
4. Anaya DA, Lahat G, Wang X, et al.: Establishing prognosis in retroperitoneal sarcoma: A new histology-based paradigm. Ann Surg Oncol 2009;16:667-675.
5. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856.
6. Zagars GK, Ballo MT, Pisters PW, et al.: Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 2003;97:2544-2553.
7. Pisters PW, Pollock RE, Lewis VO, et al.: Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg 2007;246:675-681 discussion 681-672.
8. Zagars GK, Ballo MT, Pisters PW, et al.: Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: An analysis of 1225 patients. Cancer 2003;97:2530-2543.
9. Lin PP, Guzel VB, Pisters PW, et al.: Surgical management of soft tissue sarcomas of the hand and foot. Cancer 2002;95:852-861.
10. Sadoski C, Suit HD, Rosenberg A, et al.: Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-230.
11. Swallow CJ, Catton CN: Local management of adult soft tissue sarcomas. Semin Oncol 2007;34:256-269.
12. Tukiainen E, Bohling T, Huuhtanen R: Soft tissue sarcoma of the trunk and extremities. Scand J Surg 2003;92:257-263.
13. Parsons JT, Zlotecki RA, Reddy KA, et al.: The role of radiotherapy and limb-conserving surgery in the management of soft-tissue sarcomas in adults. Hematol Oncol Clin North Am 2001;15:377-388, vii.
14. Rosenberg SA, Tepper J, Glatstein E, et al.: The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-315.
15. Ballo MT, Zagars GK: Radiation therapy for soft tissue sarcoma. Surg Oncol Clin N Am 2003;12:449-467 vii.
16. Davis AM, O'Sullivan B, Turcotte R, et al.: Late radiation morbidity following randomization to preoperative versus post-operative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005;75:48-53.
17. O'Sullivan B, Davis AM, Turcotte R, et al.: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 2002;359:2235-2241.
18. Davis AM, O'Sullivan B, Bell RS, et al.: Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472-4477.
19. Demetri GD, Antonia S, Benjamin RS, et al.: National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology-v.1.2009. In, 2009.
20. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-1654.
21. Pervaiz N, Colterjohn N, Farrokhyar F, et al.: A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573-581.
22. Frustaci S, Gherlinzoni F, De Paoli A, et al.: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-1247.
23. Frustaci S, De Paoli A, Bidoli E, et al.: Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65:80-84.
24. Pinedo HM, Vendrik CP, Bramwell VH, et al.: Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multi-disciplinary approach. E.O.R.T.C. protocol 62771. Eur J Cancer 1979;15:811-820.
25. Woll MvG PJ, Hohenberger P, Le Cesne A, et al.: EORTC Soft Tissue & Bone Sarcoma Group: Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, Vol. 25, No 18S (June 20 Supplement), 2007: 10008.
26. Gortzak E, Azzarelli A, Buesa J, et al.: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096-1103.
27. Engel CJ, Eilber FR, Rosen G, et al.: Preoperative chemotherapy for soft tissue sarcomas of the extremities: The experience at the University of California, Los Angeles. Cancer Treat Res 1993;67:135-141.
28. Wanebo HJ, Temple WJ, Popp MB, et al.: Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer 1995;75:2299-2306.
29. Wanebo HJ, Temple WJ, Popp MB, et al.: Combination regional therapy for extremity sarcoma. A tricenter study. Arch Surg 1990;125:355-359.
30. Eilber FC, Rosen G, Eckardt J, et al.: Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001;19:3203-3209.
31. Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumours. Ann Chir Gynaecol 1998;87:278-281.
32. Trent JC, Beach J, Burgess MA, et al.: A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003;98:2693-2699.
33. Nilsson B, Bumming P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - A population-based study in western Sweden. Cancer 2005;103: 821-829.
34. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
35. Fletcher CD, Berman JJ, Corless C, et al.: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-465.
36. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-1134.
37. Blanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632.
38. Eisenberg BL, Judson I: Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-475.
39. Eisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:42-47.
40. Lucas DR, Kshirsagar MP, Biermann JS, et al.: Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: Clinicopathological correlation. Oncologist 2008;13:451-458.
41. Menendez LR, Ahlmann ER, Savage K, et al.: Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma. Clin Orthop Relat Res 2007;455:219-224.
42. Henshaw RM, Priebat DA, Perry DJ, et al.: Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol 2001;8:484-495.
43. Schmidt RA, Conrad EU III, Collins C, et al.: Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 1993;72:2593-2601.
44. Pezzi CM, Pollock RE, Evans HL, et al.: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1990;211:476-481.